Archynetys Live news trend intelligence
◼ Archived Health 🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

Takeda's Qdenga has become the first dengue vaccine approved for use in India, targeting one of the world's most at-risk populations.

By · Published July 23, 2026  04:01 UTC · Updated July 23, 2026  09:27 UTC

7sources
8articles
5velocity
+0%since first seen
91d agofirst detected
Text:
🤖 AI Dossier

Evidence dossier

Intelligence passport

66/100 Strong
7distinct sources shown
40velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

📍 The outcome

India approved Takeda's Qdenga as the country's first dengue vaccine. The DCGI cleared the vaccine for individuals aged 4 to 60 years.

Epilogue added 88d ago, after coverage quieted.

Answered

Who is eligible for the Qdenga vaccine in India?

The vaccine is approved for individuals aged 4 to 60 years.

Which company developed the vaccine?

The vaccine was developed by the Japanese drugmaker Takeda.

Is this the first dengue vaccine approved in India?

Yes, Qdenga is India's first approved dengue vaccine.

Where it stands

⚡ Executive Intelligence Takeaways Corroborated across 7 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 7 distinct news outlets with 8 published articles, achieving a live velocity of 5.
  • Primary Driver: Takeda's Qdenga has become the first dengue vaccine approved for use in India, targeting one of the world's most at-risk populations.
  • Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

India's Drug Controller General of India (DCGI) has cleared Takeda's Qdenga for use. The vaccine is approved for individuals between the ages of 4 and 60 years.

Coverage from Reuters, The Hindu, The Indian Express, and NDTV emphasizes the vaccine's role as the first of its kind in the country. The Times of India reports on the challenges of immunity regarding the four virus strains and notes a chemical trial conducted by a city-based private university.

Future developments include the implementation of the vaccine for the eligible age group and the ongoing management of dengue virus strain immunity.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 89d ago.

Who reported it (8)

Momentum

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📊 AUDIENCE & LONGEVITY PULSE

How do you expect this trend to evolve over the next 24 hours?

Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.

Select an assessment to vote. Verified Reader Intelligence

Topics

Takeda Qdenga India DCGI Dengue

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →